



Immune Responses to SARS-CoV-2 Vaccines

Guest Editors:

Dr. Ge Song

The Scripps Research Institute, La Jolla, CA, USA

Dr. Rami Musharrafieh

The Scripps Research Institute, La Jolla, CA, USA

Deadline for manuscript submissions:
closed (31 August 2023)

Message from the Guest Editors

Although it has been almost three years combating COVID-19, a disease caused by SARS-CoV-2 which has led to more than 6.5 million deaths worldwide, major aspects of the immune response following vaccination and/or infection remain to be fully understood. While multiple vaccines have been established which effectively slowed the pandemic, details of the short- and long-term immunity shaped by vaccines require a more comprehensive evaluation given the narrow timeline set for their development and deployment. Studies of immune responses to SARS-CoV-2 vaccines may guide the improvement of current and future vaccines and provide the immunological framework for eliciting potent responses by vaccination in the event of a future SARS-like coronavirus spillover.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)